Literature DB >> 23117003

Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012.

Edmund Chiong1, Miah Hiang Tay, Min Han Tan, Santosh Kumar, Hong Gee Sim, Bin Tean Teh, Rainy Umbas, Noan Minh Chau.   

Abstract

Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries. These limitations, which include financial and logistical challenges and lack of skilled health-care professionals, have the greatest effect in low-income countries. This consolidated statement gives treatment recommendations for renal-cell carcinoma that are based on clinical evidence and stratified according to extent of resource availability. The statement was formulated by a panel of urologists, medical oncologists, and clinical oncologists from Asian countries, at a consensus session on kidney cancer that was held as part of the 2012 Asian Oncology Summit in Singapore. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), and treatment recommendations are specified based on availability of financial, skill, and logistical resources.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117003     DOI: 10.1016/S1470-2045(12)70433-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  11 in total

1.  Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.

Authors:  Yuan Chang; Le Xu; Huimin An; Qiang Fu; Lian Chen; Zongming Lin; Jiejie Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma.

Authors:  Yuting Liu; Donghao Shang
Journal:  Mol Cell Biochem       Date:  2019-12-17       Impact factor: 3.396

3.  Induction of cell cycle arrest, DNA damage, and apoptosis by nimbolide in human renal cell carcinoma cells.

Authors:  Yi-Hsien Hsieh; Chien-Hsing Lee; Hsiao-Yun Chen; Shu-Ching Hsieh; Chia-Liang Lin; Jen-Pi Tsai
Journal:  Tumour Biol       Date:  2015-04-28

4.  Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells.

Authors:  Chu-Che Lee; Po-Yu Huang; Yi-Hsien Hsieh; Yong-Syuan Chen; Jen-Pi Tsai
Journal:  Tzu Chi Med J       Date:  2021-10-21

5.  P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.

Authors:  Zheng Liu; Yidong Liu; Le Xu; Huimin An; Yuan Chang; Yuanfeng Yang; Weijuan Zhang; Jiejie Xu
Journal:  Cancer Sci       Date:  2015-07-29       Impact factor: 6.716

6.  Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.

Authors:  Shukui Qin; Feng Bi; Jie Jin; Ying Cheng; Jun Guo; Xiubao Ren; Yiran Huang; Jamal Tarazi; Jie Tang; Connie Chen; Sinil Kim; Dingwei Ye
Journal:  Onco Targets Ther       Date:  2015-06-08       Impact factor: 4.147

7.  MCPIP1 contributes to clear cell renal cell carcinomas development.

Authors:  Janusz Ligeza; Paulina Marona; Natalia Gach; Barbara Lipert; Katarzyna Miekus; Waclaw Wilk; Janusz Jaszczynski; Andrzej Stelmach; Agnieszka Loboda; Jozef Dulak; Wojciech Branicki; Janusz Rys; Jolanta Jura
Journal:  Angiogenesis       Date:  2017-02-14       Impact factor: 9.596

8.  Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9.

Authors:  Min-Hong Hsieh; Jen-Pi Tsai; Shun-Fa Yang; Hui-Ling Chiou; Chia-Liang Lin; Yi-Hsien Hsieh; Horng-Rong Chang
Journal:  Cells       Date:  2019-08-21       Impact factor: 6.600

9.  Prognostic value of the albumin-to-alkaline phosphatase ratio on urologic outcomes in patients with non-metastatic renal cell carcinoma following curative nephrectomy.

Authors:  Aidan Xia; Yuming Chen; Jingfeng Chen; Yue Pan; Lianmin Bao; Xiaomin Gao
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

10.  Trends in the incidence and mortality of kidney cancer in Lithuania from 1993 to 2012.

Authors:  Aušvydas Patašius; Agnė Ulytė; Albertas Ulys; Giedrė Smailytė
Journal:  Acta Med Litu       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.